Callos Andrew 4

What Happened
Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics (CYTK), exercised stock options and immediately sold the resulting 886 shares on March 2, 2026. He paid $37.63 per share to exercise (total exercise cost $33,340) and sold the 886 shares in an open-market transaction at $61.62 per share for total proceeds of $54,595. The filing also shows the related option instrument converted/disposed (reported at $0), reflecting the option's conversion into the shares sold.

Key Details

• Transaction date: 2026-03-02
• Exercise (code M): 886 shares acquired at $37.63 per share; total reported cost $33,340
• Sale (code S): 886 shares sold in open market at $61.62 per share; total proceeds $54,595
• Derivative conversion: option reported disposed at $0, consistent with conversion into shares upon exercise
• Shares owned after transaction: Not disclosed in this filing
• Footnote: The underlying option vests over 4 years in equal monthly installments (100% vested at 4 years)
• Filing timeliness: No late filing flag indicated in the report

Context
This is a same-day exercise-and-sell (cashless-style) transaction: the insider exercised vested options and sold the resulting shares immediately. Such transactions commonly reflect liquidity or tax-management actions rather than a long-term buy/sell signal; the filing itself does not state the insider’s motivation.